358 related articles for article (PubMed ID: 8113959)
1. Liposomal muramyl tripeptide up-regulates interleukin-1 alpha, interleukin-1 beta, tumor necrosis factor-alpha, interleukin-6 and interleukin-8 gene expression in human monocytes.
Asano T; McWatters A; An T; Matsushima K; Kleinerman ES
J Pharmacol Exp Ther; 1994 Feb; 268(2):1032-9. PubMed ID: 8113959
[TBL] [Abstract][Full Text] [Related]
2. Muramyl tripeptide phosphatidylethanolamine encapsulated in liposomes stimulates monocyte production of tumor necrosis factor and interleukin-1 in vitro.
Maeda M; Knowles RD; Kleinerman ES
Cancer Commun; 1991; 3(10-11):313-21. PubMed ID: 1722107
[TBL] [Abstract][Full Text] [Related]
3. Anti-(tumor necrosis factor) alters the response of human monocytes to liposomal muramyl tripeptide.
Maeda M; Asano T; Kleinerman ES
Cancer Immunol Immunother; 1993 Aug; 37(3):203-8. PubMed ID: 8334682
[TBL] [Abstract][Full Text] [Related]
4. Liposome-encapsulated muramyl tripeptide up-regulates monocyte chemotactic and activating factor gene expression in human monocytes at the transcriptional and post-transcriptional levels.
Asano T; Matsushima K; Kleinerman ES
Cancer Immunol Immunother; 1994 Jan; 38(1):16-22. PubMed ID: 8299114
[TBL] [Abstract][Full Text] [Related]
5. Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy.
Asano T; Kleinerman ES
J Immunother Emphasis Tumor Immunol; 1993 Nov; 14(4):286-92. PubMed ID: 8280710
[TBL] [Abstract][Full Text] [Related]
6. Effect of Adriamycin on liposomal muramyl tripeptide's ability to up-regulate monocyte cytokine expression.
Asano T; Fujimaki W; McWatters A; An T; Matsushima K; Kleinerman ES
Cancer Immunol Immunother; 1993 Nov; 37(6):408-11. PubMed ID: 8242665
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration.
Kleinerman ES; Jia SF; Griffin J; Seibel NL; Benjamin RS; Jaffe N
J Clin Oncol; 1992 Aug; 10(8):1310-6. PubMed ID: 1634921
[TBL] [Abstract][Full Text] [Related]
8. Effect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): can ibuprofen reduce fever and chills without compromising immune stimulation?
Fujimaki W; Griffin JR; Kleinerman ES
Cancer Immunol Immunother; 1993; 36(1):45-51. PubMed ID: 8422667
[TBL] [Abstract][Full Text] [Related]
9. Lack of production of interleukin 1 by human blood monocytes activated to the antitumor state by liposome-encapsulated muramyl tripeptide.
Tandon P; Utsugi T; Sone S
Cancer Res; 1986 Oct; 46(10):5039-44. PubMed ID: 3489519
[TBL] [Abstract][Full Text] [Related]
10. Liposomal muramyl tripeptide upregulates adhesion molecules on the surface of human monocytes.
Asano T; McIntyre BW; Bednarczyk JL; Wygant JN; Kleinerman ES
Oncol Res; 1995; 7(5):253-7. PubMed ID: 8534931
[TBL] [Abstract][Full Text] [Related]
11. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.
Kleinerman ES
Hematol Oncol Clin North Am; 1995 Aug; 9(4):927-38. PubMed ID: 7490249
[TBL] [Abstract][Full Text] [Related]
12. Induction of serum tumor necrosis factor-alpha and interleukin-6 activity by liposome-encapsulated muramyl tripeptide-phosphatidylethanolamine (L-MTP-PE) in normal cats.
Fox LE; King RR; Shi F; Kurzman ID; MacEwen EG; Kubilis PS
Cancer Biother; 1994; 9(4):329-40. PubMed ID: 7719380
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation.
Kleinerman ES; Meyers PA; Raymond AK; Gano JB; Jia SF; Jaffe N
J Immunother Emphasis Tumor Immunol; 1995 Apr; 17(3):181-93. PubMed ID: 7613644
[TBL] [Abstract][Full Text] [Related]
14. Modulation of monocyte functions by muramyl tripeptide phosphatidylethanolamine in a phase II study in patients with metastatic melanoma.
Liebes L; Walsh CM; Chachoua A; Oratz R; Richards D; Hochster H; Peace D; Marino D; Alba S; Le Sher D
J Natl Cancer Inst; 1992 May; 84(9):694-9. PubMed ID: 1569602
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo effect of doxorubicin combined with liposome-encapsulated muramyl tripeptide on canine monocyte activation.
Shi F; MacEwen EG; Kurzman ID
Cancer Res; 1993 Sep; 53(17):3986-91. PubMed ID: 8358727
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo production of interleukin-6 induced by muramyl peptides and lipopolysaccharide in normal dogs.
Shi F; Kurzman ID; MacEwen EG
Cancer Biother; 1995; 10(4):317-25. PubMed ID: 8590897
[TBL] [Abstract][Full Text] [Related]
17. Induction and maintenance of monocyte cytotoxicity during treatment with liposomes containing muramyl tripeptide despite tachyphylaxis to the cytokine response.
Galligioni E; Favaro D; Santarosa M; Quaia M; Spada A; Freschi A; Alberti D
Clin Cancer Res; 1995 May; 1(5):493-9. PubMed ID: 9816008
[TBL] [Abstract][Full Text] [Related]
18. Effect of liposome-muramyl tripeptide combined with recombinant canine granulocyte colony-stimulating factor on canine monocyte activity.
Kurzman ID; Cheng H; MacEwen EG
Cancer Biother; 1994; 9(2):113-21. PubMed ID: 7529085
[TBL] [Abstract][Full Text] [Related]
19. Comparative interaction of free and liposome-encapsulated nor-muramyl dipeptide or muramyl tripeptide phosphatidylethanolamine (3H-labelled) with human blood monocytes.
Fogler WE; Fidler IJ
Int J Immunopharmacol; 1987; 9(2):141-50. PubMed ID: 3583507
[TBL] [Abstract][Full Text] [Related]
20. Cytokine production and immune cell activation in melanoma patients treated with liposomal muramyl tripeptide (CGP 19835A lipid).
Fujimaki W; Itoh K; An T; Gano JB; Ross MI; Mansfield PF; Balch CM; Augustus LB; Karkevitch DD; Johnston D
Cancer Biother; 1993; 8(4):307-18. PubMed ID: 7804372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
